A randomized multicenter phase II trial of a sequential chemotherapy of nab-paclitaxel + gemcitabine followed by FOLFIRI.3 versus nab-paclitaxel + gemcitabine in first line of pancreatic adenocarcinoma

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2015
This article has no abstract
Epistemonikos ID: c628cb9e3d3dcf0784002f9fc47151d224abf242
First added on: Aug 25, 2022